drugset / Trial / NCT03026933

Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03026933

Phase 3 Completed 215 enrolled Kuhnil Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.

Timeline

Start
2014-05
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject KI1107 Unknown
Comparator Rosuvastatin Small molecule 20 mg

Indications